BLRX

Biolinerx

• TipRanks·2h ago

  BioLineRx, Hemispherian initiate clinical trial of GLIX1

• Reuters·5h ago

  BioLineRx partner Hemispherian starts Phase 1/2a GLIX1 trial in glioblastoma

• Reuters·03/31 20:20

  BioLineRx files Form 3 as Director Sandra Panem reports beneficial ownership

• Reuters·03/31 20:12

  BioLineRx files Form 3 for Director Raphael Hofstein initial beneficial ownership statement

• Reuters·03/31 20:12

  BioLineRx files Form 3 disclosing director Rami Dar beneficial ownership

• Reuters·03/31 20:02

  BioLineRx files initial beneficial ownership statement for director Avraham Molcho

• Reuters·03/30 22:15

  BioLineRx director Gal Cohen files initial beneficial ownership statement

• Reuters·03/30 22:15

  BioLineRx files Form 3 as director Aharon Schwartz reports stake

• TipRanks·03/28 03:55

  BioLineRx: Advancing GLIX1 and Motixafortide Pipeline with Strengthened IP and Legal Position Underpinning Buy Rating and $12 Target

• Reuters·03/27 20:07

  BioLineRx files initial beneficial ownership statement; CEO Philip A. Serlin reports 5.1 million ordinary shares owned directly

• TipRanks·03/26 11:28

  BioLineRx Launches First-in-Human Trial of GLIX1 for Glioblastoma

• Benzinga·03/26 11:17

  BioLineRx Launches First Human Trial For Brain Cancer Drug

• Reuters·03/26 11:01

  BioLineRx initiates Phase 1/2a GLIX1 trial in recurrent glioblastoma; data narrows to H1 2027

• Reuters·03/26 11:00

  BIOLINERX ANNOUNCES INITIATION OF PHASE 1/2A STUDY OF GLIX1 FOR THE TREATMENT OF GLIOBLASTOMA (GBM)

• PR Newswire·03/26 11:00

  BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)